Aspen extends rally after CEO flags vaccine, diabetes deals
Aspen Pharmacare Holdings shares extended their rally after the chief executive officer of Africa’s largest drugmaker said it has agreed to deals to produce more vaccines and other treatments for diseases such as diabetes and cancer.
Technical transfer projects have started with four multinational customers for these drugs, CEO Stephen Saad said in an interview Wednesday. He declined to give further details of who is purchasing the products from the Durban, South Africa-based company.
The drugmaker raised its forecast for sales from its existing unused sterile manufacturing lines almost threefold to at least R8-billion as it reported first-half results. By next year, Aspen anticipates receiving R2-billion from the use of available sterile manufacturing capacity, with this contribution doubling by 2025.
The shares rose as much as 8.6% on Thursday and were trading 5.6% higher by 10:33 a.m in Johannesburg. That boosts their two-day gain to 20%, the most in almost three years. Wednesday’s jump in the stock was the biggest since January 2000.
Aspen is seeking to make the most of underutilised production capacity after it set up the ability to produce its own-branded Covid-19 vaccine, only for orders to dry up. Making those shots was always seen as a stepping stone toward developing other profitable product lines, a transition the company is now accelerating, Saad said.
“We are very focused on filling this capacity and with a lot more urgency than we thought we needed because of what’s happened with the Covid vaccines,” Saad said.
The company’s technical transfer project with the Serum Institute of India to make and distribute four Aspen-branded vaccines in Africa is also well advanced and orders are expected in the first six months of next year, Saad said.
In the meantime, grant funding from the Bill & Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations has helped to partially offset the related costs.
Comments
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation